Though the approach aiming at enhancing glycosuria by inhibiting renal-specific SGLT2 has been validated effectively in diabetic patients, SGLT2 inhibitors increase compensatory polyphagia and excessive water loss, and elevate hematocrit and the incidence of urinary tract infection (8, 11, 12). Here, SLC5A2 is linked to urinary tract infection.